Literature DB >> 19406363

Dynamic contrast-enhanced breast MR imaging.

Marianne Moon1, Daniel Cornfeld, Jeffrey Weinreb.   

Abstract

This article discusses the basic principles of dynamic contrast-enhanced MR imaging (DCE-MR imaging) of the breast, including technical parameters, image acquisition, and image interpretation. Clinical DCE-MR imaging of the breast has undergone considerable growth from a once investigational technique to an important clinical tool in widespread use. Progress in MR technology and refinement of MR imaging parameters now allow for concurrent acquisition of high-spatial-resolution and adequate-temporal-resolution images, which are necessary for accurate assessment of breast lesion morphology and qualitative kinetic analysis. More advanced DCE-MR imaging techniques involving higher-temporal-resolution images and rigorous quantitative analysis of the time signal enhancement curves are currently an area of research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406363     DOI: 10.1016/j.mric.2009.01.010

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  27 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  (1)H MR spectroscopy with external reference solution at 1.5 T for differentiating malignant and benign breast lesions: comparison using qualitative and quantitative approaches.

Authors:  Waka Mizukoshi; Eito Kozawa; Kaiji Inoue; Naoko Saito; Naoko Nishi; Toshiaki Saeki; Fumiko Kimura
Journal:  Eur Radiol       Date:  2012-07-10       Impact factor: 5.315

3.  Photoacoustic angiography of the breast.

Authors:  Robert A Kruger; Richard B Lam; Daniel R Reinecke; Stephen P Del Rio; Ryan P Doyle
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

4.  The clinical value of dynamic contrast-enhanced MRI in differential diagnosis of malignant and benign ovarian lesions.

Authors:  Xian Li; Jun-Li Hu; Lai-Min Zhu; Xin-Hai Sun; Hua-Qiang Sheng; Ning Zhai; Xi-Bin Hu; Chu-Ran Sun; Bin Zhao
Journal:  Tumour Biol       Date:  2015-02-28

5.  Influence of scan duration on the estimation of pharmacokinetic parameters for breast lesions: a study based on CAIPIRINHA-Dixon-TWIST-VIBE technique.

Authors:  Wen Hao; Bin Zhao; Guangbin Wang; Cuiyan Wang; Hui Liu
Journal:  Eur Radiol       Date:  2014-10-17       Impact factor: 5.315

6.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

7.  Fat suppression techniques for breast MRI: Dixon versus spectral fat saturation for 3D T1-weighted at 3 T.

Authors:  Anastasia Kalovidouri; Natacha Firmenich; Benedicte M A Delattre; Marlise Picarra; Christoph D Becker; Xavier Montet; Diomidis Botsikas
Journal:  Radiol Med       Date:  2017-06-22       Impact factor: 3.469

8.  Preliminary experience using dynamic MRI at 3.0 Tesla for evaluation of soft tissue tumors.

Authors:  Michael Yong Park; Won-Hee Jee; Sun Ki Kim; So-Yeon Lee; Joon-Yong Jung
Journal:  Korean J Radiol       Date:  2012-12-28       Impact factor: 3.500

9.  Differentiation of malignant and benign breast lesions using magnetization transfer imaging and dynamic contrast-enhanced MRI.

Authors:  Samantha L Heller; Linda Moy; Sherlin Lavianlivi; Melanie Moccaldi; Sungheon Kim
Journal:  J Magn Reson Imaging       Date:  2012-10-23       Impact factor: 4.813

10.  A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism.

Authors:  Eric M Gale; Hsiao-Ying Wey; Ian Ramsay; Yi-Fen Yen; David E Sosnovik; Peter Caravan
Journal:  Radiology       Date:  2017-11-08       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.